Full-Time

Regional Director

Medical Science Liaison, US West

Updated on 7/23/2026

Capricor Therapeutics

Capricor Therapeutics

201-500 employees

Biotech developing cell- and exosome therapeutics

Compensation Overview

$200k - $250k/yr

Remote in USA

Remote

Remote role with periodic on-site at Capricor's San Diego HQ; domestic travel 60-75%.

Category
Biology & Biotech (1)

Get referred to Capricor Therapeutics

Find people who can refer or advise you

Requirements
  • Advanced clinical degree required (MD, PharmD, PhD, DO, or equivalent).
  • 5 to 10 years of MSL experience in biotech / pharma; experience in rare disease, cell / gene therapy, pediatrics, neuromuscular disease, or cardiology preferred.
  • Established scientific credibility and ability to engage KOLs in peer-to-peer scientific exchange.
  • Strong working knowledge of FDA, OIG, PhRMA Code, ACCME, and MLR review processes.
  • Excellent written and verbal scientific communication skills, including ability to deliver complex data to clinical audiences.
  • Self-directed execution and the ability to operate independently in a field-based environment.
Responsibilities
  • Develop and execute the territory KOL/HCP engagement plan, including identification, mapping, and prioritization of thought leaders, prescribers and treatment centers.
  • Deliver scientific presentations and engage in scientific exchange with KOLs and HCPs on Deramiocel clinical data, the DMD cardiomyopathy landscape, and emerging evidence.
  • Support advisory boards, scientific symposia, and KOL-led research initiatives.
  • Identify and support investigator-initiated studies (IIS) and real-world evidence opportunities in coordination with HEOR / RWE and Medical Director.
  • Provide scientific support for medical congresses, including DMD, neuromuscular, cardiology, and rare-disease forums.
  • Collect and synthesize field insights on clinical practice, treatment decision-making, and emerging evidence; translate insights into recommendations for medical strategy.
  • Provide scientific training and support to internal stakeholders (Sales, Market Access, Patient Services) in compliance with channel and engagement rules.
  • Maintain comprehensive scientific fluency on Deramiocel clinical data, DMD natural history, and the broader treatment landscape.
  • Ensure timely reporting of adverse events and product complaints in line with company and regulatory processes.
  • Document field activities, KOL/HCP engagement, and insights in Capricor's medical CRM in compliance with standards.
  • Ensure all activities follow FDA, OIG, PhRMA Code, ACCME, and Capricor compliance standards.
  • Perform other duties as may be assigned from time to time.
Desired Qualifications
  • Existing relationships across the DMD treatment center network, neuromuscular community, or pediatric cardiology community.
  • Prior launch experience in rare disease, cell / gene therapy, pediatrics, rare cardiology or neuromuscular disease.
  • Experience operating in a pre-commercial or early-commercial company.
Capricor Therapeutics

Capricor Therapeutics

View

Capricor Therapeutics develops cell- and exosome-based therapies to treat serious diseases. Its products use cells or tiny vesicles released by cells to repair heart tissue, Duchenne muscular dystrophy, and COVID-19–related complications, and are advanced through research and clinical trials before potential commercialization. It differentiates itself by focusing on cell- and exosome-based approaches rather than small molecules, pursuing a portfolio aimed at high-need conditions. The company’s goal is to improve patient outcomes by validating these therapies and bringing them to hospitals and healthcare providers, supported by partnerships and grants.

Company Size

201-500

Company Stage

IPO

Headquarters

Beverly Hills, California

Founded

2005

Get referred to Capricor Therapeutics

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • HOPE-3 met primary PUL 2.0 and key cardiac endpoints, strengthening approval odds.[3][5]
  • Capricor targets an August 22, 2026 PDUFA decision for deramiocel.[3][5]
  • The company is expanding manufacturing capacity and commercial infrastructure before launch.[3]

What critics are saying

  • FDA review remains binary after the earlier CRL and resubmission process.[5]
  • The NS Pharma dispute threatens U.S. commercialization even if approval arrives.[3]
  • Capricor remains highly dependent on deramiocel, with preclinical exosome programs unproven.[1][3]

What makes Capricor Therapeutics unique

  • Deramiocel is an allogeneic cardiac-derived cell therapy for Duchenne muscular dystrophy.[3]
  • Capricor combines cell therapy and proprietary exosome platforms in rare diseases.[1][3]
  • Its U.S. commercialization agreement with Nippon Shinyaku adds an external launch channel.[3]

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

Remote Work Options

Unlimited Paid Time Off

Flexible Work Hours

Paid Vacation

Staff Training (not in predefined)

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

1%
Capricor Therapeutics, Inc.
Mar 25th, 2026
Capricor Therapeutics Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

SAN DIEGO, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell…...

Capricor Therapeutics, Inc.
Mar 25th, 2026
Capricor Therapeutics Announces $23 Million Registered Direct Offering

SAN DIEGO, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development…...

Capricor Therapeutics, Inc.
Mar 25th, 2026
Capricor Therapeutics Announces Closing of $5.1 Million Offering Priced At-the-Market

LOS ANGELES, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on…...

Capricor Therapeutics, Inc.
Mar 25th, 2026
Capricor Therapeutics Provides Corporate Update and Reports First Quarter 2016 Financial Results

HOPE-Duchenne and ALLSTAR Clinical Trials on Track to Complete Enrollment in the Third Quarter Company to Host Conference Call and Webcast at 4:30…...

Capricor Therapeutics, Inc.
Mar 25th, 2026
Capricor Therapeutics Announces $7 Million Private Placement of Common Stock

Institutional Investors Include: Broadfin Capital, LLC and Sabby Capital, LLC LOS ANGELES, Feb. 4, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics,…...